Since the reduction in non-fatal MI in the LEADER trial was not significant enough to explain the impressive 22% in CV mortality, what factors do you think might have played a role?

Since the reduction in non-fatal MI in the LEADER trial was not significant enough to explain the impressive 22% in CV mortality, what factors do you think might have played a role?

Since the reduction in non-fatal MI in the LEADER trial was not significant enough to explain the impressive 22% in CV mortality, what factors do you think might have played a role?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center Past President, Science and Medicine American Diabetes Association